Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells – red blood cells, white blood cells and platelets.
The collaboration will be Sensyne Health’s fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion. No financial terms have been disclosed.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“This new collaboration with one of the world’s leading pharmaceutical companies is a further validation of Sensyne’s unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”